Get breaking news alerts via email

Click here to manage your alerts
FDA approves Cubist antibiotic for skin infections
New drugs » Sivextro is second antibiotic approved in a month to battle bacteria.
First Published Jun 20 2014 05:28 pm • Last Updated Jun 21 2014 03:41 pm

Washington • The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.

Regulators cleared the company’s Sivextro as a pill and as an intravenous solution for adults with skin infections caused by bacteria that are often resistant to older antibiotics.

Join the Discussion
Post a Comment

It’s the second FDA approval in less than a month for a new antibiotic to treat such infections. In late May, the FDA approved a similar drug from Durata Therapeutics Inc.

Antibiotics like penicillin and streptomycin first became widely available in the 1940s, and today dozens are still used to kill or suppress the bacteria behind illnesses ranging from strep throat to urinary-tract infections. The drugs are considered one of the greatest advances in the history of medicine, and have saved countless lives.

But in recent decades some common bacteria have grown resistant to antibiotics that were once highly effective. Experts say overuse and misuse of the drugs by physicians has contributed to the rise of these so-called superbugs.

The FDA gave Sivextro an expedited review under a 2012 law designed to encourage drugmakers to invest in researching and development of new antibiotics. Under the measure, Cubist will receive an additional five years of exclusive marketing rights to the drug.

Sivextro is designed to be taken over six days as a daily intravenous infusion or as a tablet. Cubist says the oral form of the drug gives patients the option of completing therapy at home, which could cut down on hospital-stay costs.

The drug works against a variety of common bacteria, including Staphylococcus aureus, Streptococcus species and Enterococcus faecalis.

The Centers for Disease Control and Prevention estimated last year that the staph infection methicillin-resistant Staphylococcus aureus, or MRSA, kills about 11,000 people annually.

The most common side effects seen in company studies were nausea, headache, diarrhea, vomiting and dizziness.

story continues below
story continues below

Lexington, Mass.-based Cubist gets more than 80 percent of its revenue from a single product: the antibiotic Cubicin, which is used to treat infections of the skin and blood. Last fall the company paid $1.24 billion to acquire rival drugmakers Trius Therapeutics and Optimer Pharmaceuticals Inc., both developers of antibiotics.

Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment

About Reader Comments

Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Access your e-Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.